Such findings have subsequently led to efforts to discover ATPase inhibitors, however the currently described inhibitors are dual inhibitors of SMARCA2/4 and are hampered by dose-limiting tolerability issues, preventing the full in vivo exploration of anti-tumor activity14. Here, SMARCA2 is linked to neoplasm.